We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

DECLIC Patient Education Program : Assessment Through a Population Health Intervention Research Approach (LE DECLIC EPRI)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04634097
Recruitment Status : Recruiting
First Posted : November 18, 2020
Last Update Posted : September 23, 2021
Sponsor:
Information provided by (Responsible Party):
Institut Curie

Brief Summary:
Cancer pain is a frequent symptom, reported by 20 to 70% of patients in any stage of the cancer disease : 60 to 70% in the advanced stage of the disease and 20 to 40% among the survivors. Among patients who report pain, 40% report undertreated pain. Strengthening Pain management in cancer is a specific objective of the French Cancer Plan. Providing patient education for cancer pain management is recommended since small to moderate efficacy of patient education on pain intensity and interference was found in all meta-analysis. An effect size comparable with some analgesic agents. However, recommendations suggest improvement in order to increase effectiveness and population reach of those interventions. The DECLIC EPRI intervention aim at addressing all the issues raised by patient education for cancer pain management. It was developed according to the framework of Michie's Behavior change wheel theory.

Condition or disease Intervention/treatment Phase
Cancer Patients With Cancer Pain Other: Experimental group Other: standrad group Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 270 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:

Control group : Standard follow-up patient related to pain. Specific to each center : with or without existing local ETP program (standard care).

Experimental group : Clusters will be proposed LE DECLIC EPRI intervention, which is a complex intervention, associating 3 components,:

A. DECLIC program set up in the centers, open to concerned patients.

B. 3 training sessions :

  • one public of primary care physicians in order to give them the opportunity to be involved in the medical care in charge of the patient suffering from cancer pain.
  • one public of cancer physicians, leaders of opinions in each cancer centers participating to the study and one public of health professionals in order to train them to be educators (team building).
  • for healthcare professionals in order to train them as educators in this program.

C. The collaboration of one primary care network, specialized in pain management, in order to reinforce the patient care pathway.

Masking: None (Open Label)
Primary Purpose: Health Services Research
Official Title: DECLIC Patient Education Program : Assessment Through a Population Health Intervention Research Approach (LE DECLIC EPRI)
Actual Study Start Date : March 5, 2021
Estimated Primary Completion Date : September 5, 2024
Estimated Study Completion Date : February 1, 2025

Arm Intervention/treatment
Experimental: Experimental group

Clusters will be proposed LE DECLIC EPRI intervention, which is a complex intervention, associating 3 components,:

A. DECLIC program set up in the centers, open to concerned patients.

B. 3 training sessions :

  • one public of primary care physicians in order to give them the opportunity to be involved in the medical care in charge of the patient suffering from cancer pain.
  • one public of cancer physicians, leaders of opinions in each cancer centers participating to the study and one public of health professionals in order to train them to be educators (team building).
  • for healthcare professionals in order to train them as educators in this program.

C. The collaboration of one primary care network, specialized in pain management, in order to reinforce the patient care pathway.

Other: Experimental group

Clusters will be proposed LE DECLIC EPRI intervention, which is a complex intervention, associating 3 components,:

A. DECLIC program set up in the centers, open to concerned patients.

B. 3 training sessions :

  • one public of primary care physicians in order to give them the opportunity to be involved in the medical care in charge of the patient suffering from cancer pain.
  • one public of cancer physicians, leaders of opinions in each cancer centers participating to the study and one public of health professionals in order to train them to be educators (team building).
  • for healthcare professionals in order to train them as educators in this program.

C. The collaboration of one primary care network, specialized in pain management, in order to reinforce the patient care pathway.


Standard group
Standard follow-up patient related to pain. Specific to each center : with or without existing local ETP program (standard care).
Other: standrad group
Standard follow-up patient related to pain. Specific to each center : with or without existing local ETP program (standard care).




Primary Outcome Measures :
  1. Effectiveness of LE DECLIC EPRI intervention on the pain interference with the daily life [ Time Frame: 6 months ]
    Brief pain Inventory BPI Questionnaire


Secondary Outcome Measures :
  1. Effectiveness of the intervention on other clinical outcomes [ Time Frame: 6 months ]

    Brief pain Inventory BPI, EQ-5D, DAMS questionnaires Other dimension of the QCD : current pain, average pain and worst pain in the last 24 hours.

    Number of area identified as painfull by the patient, and surface of those area, measured on the "figures" item of the QCD.

    Quality of life, assessed with the EQ-5D, in order to transform the results into utilities for the efficiency evaluation.

    Side effects occurrence, related to the toxicity of the analgesics, assessed with a questionnaire constructed by the research team (questionnaires ad hoc).

    Occurrence of atypical pain. Date of the occurrence of atypical pain. Occurrence of epiduritis. Date of the occurrence of epiduritis. Time between atypical pain occurrence and epiduritis diagnosis. Adhesion to analgesic medications assessed with a French translation of the questionnaire DAMS (Garfield et al), standardized per analgesic.


  2. The organizational effectiveness of the intervention. [ Time Frame: 6 months ]
    Organizational effectiveness Number of GPs recruited in the training sessions. Number of other primary care professionals recruited in the training sessions. Number of consultations with the GP by patient. Number of cancer pain consultations with the GP by patient. Number of consultation by patient due to pain with the GP. Number of interactions developed between the pain management network and GPs. Number of emergency consultations and hospitalisations due to pain by patient in the center.

  3. Educational effectiveness of the intervention. [ Time Frame: 6 months ]

    quiz with certitude level assessement, sure test, HADS questionnaires, French-Canadian Chronic Pain Self-efficacy Scale (FC-CPSES).

    Knowledge, assessed with a quiz with certitude level assessement, developed specifically for the DECLIC program, by a multidisciplinary team of physicians, patients and reseachers.

    Skills assessed with scenarii (simulated cases) developed specifically for the DECLIC program, by a multidisciplinary team of physicians, patients and reseachers. Informed decision assessed with a scenario (simulated case) developed specifically for the DECLIC program, by a multidisciplinary team of physicians, patients and reseachers. Informed decision is assessed with the French version of the SURE test. Anxiety : with the HADS questionnaire. Self efficacy, with French-Canadian Chronic Pain Self-efficacy Scale (FC-CPSES).

    Sense of control with visual analogical scale. Ability to communicate with visual analogical scale developed specifically for the DECLIC program.


  4. Effectiveness of the intervention on patients value. [ Time Frame: 6 months ]

    D'Ivernois 2008 questionnaire, PAT-SAT 32 questionnaire, SMD Q9 questionnaire. Patient perceived quality of care will be assessed thanks to the medical consultation dimension of the PAT-SAT 32, a validated questionnaire in French.

    Reported share decision making, inside GPs consultation, by patient. Share decision making assessed in the center with the with the SMD Q9, validated in French.


  5. Efficiency of the intervention. [ Time Frame: 6 months ]
    Cost-effectiveness analysis.

  6. Effect of patient's caracteristics on the intervention effectiveness and participation. [ Time Frame: 6 months ]
    EDI quintile and Newest Vital Sign

  7. Implementation of the intervention [ Time Frame: 48 months ]

    participation rate in the training of GPs and KLOs, number of GPs contacting the network, number of GPs contacting the patient education team, number of oncologists referring patients to the DECLIC program, number of patients referred by oncologist, number of oncologist consulting the patient education DECLIC e-record.

    Reach :

    number of patients who agreed to participate/number of patients to whom the study was proposed.

    Reasons for refusal.


  8. Interaction between the contexts and the intervention effectiveness. [ Time Frame: 48 months ]
    Barriers and drivers to intervention adoption among KLOs and oncologists. Barriers and drivers to effective intervention in GPs. Barriers and drivers to effective intervention in patients.

  9. Mechanisms of action of the intervention. [ Time Frame: 48 months ]
    Unexpected outcomes.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Patient aged over 18.
  2. Followed in the participant comprehensive cancer center.
  3. All cancer types, location and stage.
  4. Patient under any anticancer treatment (including hormonal therapy) or patient has stopped his treatment (including hormonal therapy) maximum 2 years before inclusion.
  5. Patient experiencing cancer pain and/or his treatments for 3 months or more.
  6. All previous and concomitant treatments are accepted.
  7. Participation to another clinical trial is accepted.
  8. Patient has accepted to participate to the study and signed informed consent form or his legal representative.
  9. Patient affiliated to the social security healthcare.

Exclusion Criteria:

  1. Cognitive impairment preventing to understand the patient education program.
  2. Language barrier preventing to understand the patient education program.
  3. Physical impairment preventing patient to attend to the patient education program.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04634097


Locations
Layout table for location information
France
Institut de Cancérologie de l'Ouest Paul Papin Recruiting
Angers, France, 49000
Contact: Sabrina JUBIER-HAMON, MD    +33.2.41.35.27.00    sabrina.jubier-hamon@ico.unicancer.fr   
Principal Investigator: Sabrina JUBIER-HAMON, MD         
Institut Curie Recruiting
Paris, France, 75005
Contact: Evelyne RENAULT-TESSIER, MD    +33.1.44.32.40.40    evelyne.renault-tessier@curie.fr   
Contact: Anne-Sophie PLISSONNIER       anne-sophie.plissonnier@curie.fr   
Principal Investigator: Evelyne RENAULT-TESSIER, MD         
GH Diaconesses Croix Saint Simon (GHDCSS) Recruiting
Paris, France, 75012
Contact: Laure COPEL, MD    +33.1.44.74.28.10    lcopel@hpital-dcss.org   
Principal Investigator: Laure COPEL, MD         
AP-HP La Pitié Salpêtrière Recruiting
Paris, France, 75013
Contact: Laure SERRESSE, MD    +33.1.42.16.75.60    laure.serresse@aphp.fr   
Principal Investigator: Laure SERRESSE, MD         
Institut Curie Recruiting
Saint-cloud, France, 92210
Contact: Joy BACRIE, MD    +33.1.47.11.15.15    joy.bacrie@curie.fr   
Contact: Anne-Sophie PLISSONNIER       anne-sophie.plissonnier@curie.fr   
Principal Investigator: Joy BACRIE, MD         
Sponsors and Collaborators
Institut Curie
Layout table for additonal information
Responsible Party: Institut Curie
ClinicalTrials.gov Identifier: NCT04634097    
Other Study ID Numbers: IC 2019-06
First Posted: November 18, 2020    Key Record Dates
Last Update Posted: September 23, 2021
Last Verified: August 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Cancer Pain
Pain
Neurologic Manifestations